Fundz

TransCode Therapeutics secures up to $20 million in flexible financing to support its Phase 2a trial for TTX-MC138, ensuring operational momentum into 2027/2028.

PUBLIC · RNAZApr 07, 2026

Amount Raised

$20 Million

Round Type

Funding Round

BostonBiotechnologyHealth CareMedicalTherapeutics

Investors

Institutional Healthcare Investor

Description

TransCode Therapeutics has entered into an agreement for financing of up to $20 million with an institutional healthcare investor. The deal includes pre-paid advances of up to $6 million and a Standby Equity Purchase Agreement for an additional $14 million. This funding will help facilitate TransCode's Phase 2a trial for its lead clinical program. The agreement ensures the company maintains its operational momentum as it navigates its clinical trials.

Quick answer

TransCode Therapeutics raised $20 Million in a Funding Round round, dated April 7, 2026. Investors: Institutional Healthcare Investor. TransCode Therapeutics is based in Boston, Massachusetts, United States.

How much did TransCode Therapeutics raise?
TransCode Therapeutics raised $20 Million in a Funding Round round on April 7, 2026.
Who invested in TransCode Therapeutics?
Institutional Healthcare Investor is named as investors in this round.
What does TransCode Therapeutics do?
TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics.
Where is TransCode Therapeutics based and how big is it?
TransCode Therapeutics is based in Boston, Massachusetts, United States. Fundz records about 7 employees.
Who are the decision-makers at TransCode Therapeutics?
Fundz holds 2 contacts at TransCode Therapeutics, including the Chief Technology Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Medical and Therapeutics around the same time

Companies in the same sectors as TransCode Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Kordata Dynamics raised an undisclosed amount (Pre-Seed) on May 21, 2026.
  • Citius Oncology raised $37M on May 6, 2026.
  • TippingPoint Biosciences raised $4.5M (Seed) on March 31, 2026.
  • Sonire Therapeutics raised $18M (Series A) on March 31, 2026.
  • Diamyd Medical raised $125M (Funding Round) on March 23, 2026.
  • Combat Medical raised $3.5M (Series A) on March 12, 2026.

Who to call at TransCode Therapeutics, and when

A new round usually means TransCode Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day TransCode Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at TransCode Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at TransCode Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

TransCode Therapeutics

Location

Boston, Massachusetts, United States

About

TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. Using its proprietary iron oxide nanoparticle delivery platform, the company has created a portfolio of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. Another of the company’s drug candidates, TTX-siPDL1, focuses on treating tumors by targeting a protein called Programmed death-ligand 1 (PD-L1). TransCode also has three cancer-agnostic programs: TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I designed to drive an immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against tumor cells.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment TransCode Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsZdravka M., Chief Technology Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for TransCode Therapeutics's next move

See what Strategic adds

TransCode Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.